- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
HC asks Centre if financial aid for rare diseases covers clinical trials of experimental DMD drug
![HC asks Centre if financial aid for rare diseases covers clinical trials of experimental DMD drug HC asks Centre if financial aid for rare diseases covers clinical trials of experimental DMD drug](https://medicaldialogues.in/h-upload/2022/05/04/750x450_175585-delhi-high-court.webp)
The court said that several factors merited consideration of the competent authority on whether the expenses which are likely to be incurred in the course of administering the drug to the 54 enrolled patients would stand covered under its order.
New Delhi: The Delhi High Court has asked the Centre to state if its financial aid for the treatment of rare diseases would cover the expenses of the second and third phases of clinical trials of an experimental drug for Duchenne Muscular Dystrophy (DMD) and the treatment of children enrolled in those trials.
The court noted that a central government office memorandum of May 19 envisaged the extension of financial support up to Rs 50 lakhs for treatment of patients suffering from any of the rare diseases under the National Policy for Rare Diseases of 2021, including DMD, and the decision "could be considered" as covering the expenses in course of administration of the trial drug.
Read also: Natco Pharma dragged to Delhi HC over alleged patent violation
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751